← 483 OBSERVATION EXPLORER

FDA 483 OBSERVATION · #661 OF 1,000 MOST-CITED

Testing and standardization of standards et. al.

FDA cited this observation 26 times across 26 firms in recent inspections. Below: how it breaks down by program area and fiscal year, and real examples of how FDA worded it on Form FDA 483.

BY PROGRAM AREA
Drugs26
BY FISCAL YEAR
FY20261
FY20255
FY20232
FY20212
FY20203
FY20196
FY20184
FY20173

How FDA worded it — real examples

Laboratory records do not include complete records of any testing and standardization of laboratory reagents.

KaryoLogic Inc · Durham, North Carolina · Drugs · 2025-12-19

Laboratory records do not include complete records of any testing and standardization of laboratory reagents.

Chattem Inc · Chattanooga, Tennessee · Drugs · 2025-08-22

Laboratory records do not include complete records of any testing and standardization of laboratory reference standards.

DSC Laboratories, Inc. · Muskegon, Michigan · Drugs · 2025-07-16

Laboratory records do not include complete records of any testing and standardization of laboratory reference standards.

Hisamitsu Pharmaceutical Co., Inc. · Utsunomiya · Drugs · 2025-07-11

Laboratory records do not include complete records of any testing and standardization of laboratory reference standards and standard solutions.

Grant Industries, Inc. · Elmwood Park, New Jersey · Drugs · 2025-06-16

Laboratory records do not include complete records of any testing and standardization of laboratory reagents and standard solutions.

Tiger Balm (Malaysia) Sdn Bhd · Johor Bahru · Drugs · 2024-11-01

Related SPEQ references

Where to read the requirements behind this observation area on SPEQ. These are SPEQ's topic and audience pages — not an FDA classification of the citation.

Pharma industry

Examples are a representative sample of FDA's published inspection observations. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →